Drugs / Canephron® N
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01478620 | Oct 2011 → May 2012 | urinary tract infection | Bionorica SE | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02639520 Comparator | Dec 2015 → Jun 2017 | urinary tract infection | Bionorica SE | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Canephron N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02639520 ↗ |
| Known as | BNO 1045 | “INTRODUCTION: This randomized, controlled, Phase III non-inferiority clinical trial aimed to determine whether herbal therapy with Canephron® N (BNO 1045) is non-inferior to...” PMID 30231252 ↗ Sep 2018 |
| Modality | Traditional medicine (herbal / TCM) | “INTRODUCTION: This randomized, controlled, Phase III non-inferiority clinical trial aimed to determine whether herbal therapy with Canephron® N (BNO 1045) is non-inferior to...” PMID 30231252 ↗ Sep 2018 |
| Route | Oral | “3x 2 coated tablets/day for 7 days p.o.” NCT01478620 ↗ |